Yazar "Temel, M. Kemal" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • [ N/A ]
    Öğe
    CLINICAL UTILITY OF TENSIN 2 LEVELS AS A DIAGNOSTIC AND PROGNOSTIC BIOMARKER IN BREAST CANCER
    (Carbone Editore, 2021) Serin, Kursat Rahmi; Ucuncu, Zubeyr; Temel, M. Kemal; Bademler, Suleyman; Soydinc, Hilal Oguz; Karanlik, Hasan; Karabulut, Senem
    Background: To discuss the diagnostic and prognostic potential of tensin-2 (TNS2) levels in patients with breast cancer (BC). Methods: The study included sixty patients with BC and twenty healthy female controls for a comparative investigation of TNS2 protein and gene expression levels.. Results: Compared to the healthy controls, we found that the patient group showed a statistically significantly lower mean level of TNS2 protein (p<0.001) and higher mean level of TNS2 gene expression (p=0.015). Secondly, we examined the clinical utility of TNS2 levels as an indicator of invasiveness and aggressiveness in BC by comparing patient TNS2 levels by stage and grade. Although the measured mean values differed between the patients subgrouped by tumor biology, grade, and stage, we found that the differences were not statistically significant. Conclusion: Our findings suggest that TNS2 levels can be utilized diagnostically and prognostically, and that there is a need for further studies with larger he mean values measured differed between the patient subgroups based on tumor elucidate the clinical value of TNS2 protein and gene expression levels as an early prognosticator of aggressiveness in BC and thus a useful criterion in treatment optimization.
  • Küçük Resim
    Öğe
    Individualized Treatment Outcomes in Colorectal Cancer with Liver Metastasis
    (Hayat Sağlık ve Sosyal Hizmetler Vakfı, 2020) Serin, Kürşat Rahmi; Üçüncü, Muhammed Zübeyr; Karabay, Önder; Temel, M. Kemal; Hacim, Adnan; Terzi, Cem
    Aim: Liver metastasis (LM) is the most common cause of death in colorectal cancer (CRC). In cases of recurrent LM, individualized aggressive local treatments are recommended for better survival outcomes. In this study, we aimed to present the health outcomes obtained in a group of highly selected patients with metastatic CRC. Materials and Methods: We retrospectively reviewed the medical records of a total of 45 (28 males, 17 females) patients who were diagnosed with liver-metastatic CRC and underwent surgical treatment between March 2013 and November 2018. Results: The median patient age was 61 years. Thirty-two patients were diagnosed with synchronous metastases, and 21 of these patients underwent synchronous surgery. The median time for metachronous metastases was 18 months. Twenty-three patients developed bilobar metastases, with a median number of 4 (1–18) metastases. Eleven (10 synchronous and 1 metachronous metastasis) patients underwent liver resection without perioperative chemotherapy while the other 34 received perioperative treatment. Parenchymal-sparing liver surgery (metastasectomy/segmentectomy) as performed in 34 patients was the most preferred surgical approach and, again in accordance with the oncological principles, surgery was combined with ablation procedures to treat 31 metastases in 10 patients. The median tumor size and surgical margin width were 35 mm and 3 mm, respectively. Surgical margin positivity was present in 4 patients, of whom only 1 developed local recurrence. In a median time of 12 months, a total of 20 patients developed recurrent LM, and 12 of them underwent secondary surgery. The median survival time was 32 months for all 45 patients and 36 months for the 12 patients who underwent secondary surgery due to recurrences. Discussion and Conclusion: In CRC with LM, aggressive individualized multidisciplinary treatments can provide better survival outcomes in the long term. Synchronous or staged interventions are applicable with an acceptable morbidity and mortality. In patients with recurrent metastasis, parenchymal-sparing procedures should be preferred in order to increase the patient’s chance of repeated surgical treatment.